Guggenheim lowered the firm’s price target on SpringWorks Therapeutics (SWTX) to $77 from $78 and keeps a Buy rating on the shares. The firm is ...
Hosted on MSN1d
The New Gold Rush in Rare Disease Treatments and Merck KGaA’s Acquisition of SpringWorks TherapeuticsFor many years, the pharmaceutical business concentrated mostly on blockbuster medications, which are cures for common ...
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $40.0 and $60.0 for SpringWorks Therapeutics, spanning the last ...
Stocktwits on MSN2d
SpringWorks Therapeutics Gains Retail Interest Ahead Of Q4 Earnings – What Investors ExpectSpringWorks Therapeutics Inc. (SWTX) shares surged more than 10% in Wednesday’s after-hours, signaling strong investor ...
The latest example of this trend is Merck KGaA’s impending all-cash acquisition of SpringWorks Therapeutics, valued around ...
Reports FY24 revenue $191.5M, consensus $190.85M. “We are very pleased with the strong execution of OGSIVEO in 2024 and believe that we are ...
Tuesday, the agency signed off on SpringWorks’ Gomekli (mirdametinib) as a treatment for the rare genetic disorder ...
The U.S. Food and Drug Administration said on Tuesday it has approved SpringWorks Therapeutics' drug to treat a type of rare ...
Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare ...
SpringWorks Therapeutics (SWTX) may be acquired by Merck KGaA for $77 per share, representing a potential premium of 92% ...
As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...
Just over two years after establishing desmoidtumors.com, the drugmaker is teaming with Jennifer Fisher to empower patients.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback